AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
25/05/12
Transaction in Own Shares24/05/12
Transaction in Own Shares21/05/12
Transaction in Own Shares18/05/12
Transaction in Own Shares17/05/12
Transaction in Own Shares16/05/12
Transaction in Own Shares15/05/12
Transaction in Own Shares14/05/12
Transaction in Own Shares11/05/12
Transaction in Own Shares10/05/12
Transaction in Own Shares
21/07/11
AstraZeneca got some welcome news today when the US Food and Drug Adminstration approved its blood-thinning drug Brilinta. Analysts still have mixed views of the FTSE-100 pharmaceutical company’s shares, though
20/07/11
Question marks at the FDA about AstraZeneca’s Dapaglifozin drug have led to weakness in the company’s shares today. Analyst at three major investment banks have varying opinions of where they are headed
20/11/09
AstraZeneca’s shares currently trade at about 7.7x forecast earnings for 2010, which compares to a multiple of 10.3x for GlaxoSmithKline and 17.2x for Shire.
09/05/12
Pharma sector progressing steadily through trough year, says broker04/05/12
AstraZeneca added to UBS’s Key Calls list despite poor results30/04/12
AstraZeneca: JP Morgan Cazenove sees limited further downside; upgrades to 'neutral'26/04/12
AstraZeneca CEO quits as profits slump - UPDATE26/04/12
AstraZeneca CEO quits as profits slump23/04/12
AstraZeneca to acquire gout-focused US biotech for $1.3bln26/03/12
AstraZeneca blow over Seroquel competition20/12/11
AstraZeneca hit by drug trial disappointments; takes Q4 charge of US$381 mln08/11/11
AstraZeneca tumbles 3 per cent after trial failure and Morgan Stanley downgrade02/09/11
AstraZeneca reveals inconclusive results for its landmark SATURN study on Crestor
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
